The current recommendation for the screening of HCC in high-risk populations, endorsed by the American Association for the Study of Liver Disease (AASLD) involves ultrasound (US) with or without alpha-feto protein (AFP) measurement at 6-month intervals [5]. The gene discussed is AFP; the disease is liver disorder.